Phathom Pharmaceuticals, Inc.

Analysis for Ticker: PHAT

Phathom Pharmaceuticals Inc operates as a gastrointestinal biology venture focused on commercializing its acid-blocking drug VOQUEZNA. To the untrained eye, the company appears healthy after reporting 58,3$ million in revenue for 03/2026. However, the math reveals a host organism being systematically hollowed out from the inside. The company does not own its primary asset; it rents the rights from Takeda Pharmaceutical Company in exchange for a royalty that takes a double-digit % of every sale right off the top. Another 10% is pledged to a syndicate of shadow lenders, meaning more than 0,20$ of every 1,00$ vanishes before any bills are paid. The real crisis is the interest on their debt, which hit 15,7$ million in just three months, while their total liability for revenue interest financing has ballooned to 380,0$ million. Every share trading in a fifty-two week range of 2,21$ to 18,31$ is backed by a net tangible book value of negative 3,86$. This is an entity where the math dictates that the more it sells, the faster it bleeds for its creditors.